Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

7.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.5K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.1K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
The Ras Gene02:38

The Ras Gene

6.9K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A disease model resource reveals core principles of tissue-specific cancer evolution.

Nature·2026
Same author

RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

PloS one·2026
Same author

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Nature aging·2026
Same author

A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.

EMBO molecular medicine·2025

Related Experiment Video

Updated: Dec 24, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K

Targeting the MAPK Pathway in KRAS-Driven Tumors.

Matthias Drosten1, Mariano Barbacid1

  • 1Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain.

Cancer Cell
|April 15, 2020
PubMed
Summary

Targeting KRAS mutations in cancer remains challenging. This review explores the mitogen-activated protein kinase (MAPK) pathway, including RAF1, as potential targets for treating KRAS-mutant cancers.

Keywords:
KRAS-driven cancerMAPK pathwayclinical trialslung adenocarcinomapancreatic ductal adenocarcinoma

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.7K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.5K

Related Experiment Videos

Last Updated: Dec 24, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.4K
Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.7K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS mutations are prevalent in human cancers, affecting approximately 25% of all cases.
  • Despite advancements in targeting specific mutations like KRASG12C, most KRAS-driven tumors remain resistant to current therapies.
  • The development of selective drugs for KRAS-mutant cancers is a critical unmet need.

Purpose of the Study:

  • To review strategies for targeting the mitogen-activated protein kinase (MAPK) pathway in KRAS-mutant cancers.
  • To compare preclinical data from mouse models with clinical trial outcomes of MAPK inhibitors.
  • To evaluate RAF1 as a potential therapeutic target for KRAS-driven malignancies.

Main Methods:

  • Comparative analysis of genetic data from experimental mouse models of KRAS-driven lung and pancreatic tumors.
  • Review of clinical trial data for selective MAPK pathway inhibitors.
  • Literature review on the role of RAF1 in KRAS-mutant cancers.

Main Results:

  • The study highlights the complexity of targeting the MAPK pathway in KRAS-mutant cancers.
  • Preclinical findings in mouse models provide insights into the efficacy of MAPK inhibitors in clinical settings.
  • RAF1 emerges as a promising target for blocking KRAS-mutant cancer progression.

Conclusions:

  • Targeting the MAPK pathway, particularly RAF1, holds significant potential for treating KRAS-mutant cancers.
  • Integrating preclinical and clinical data is crucial for validating new therapeutic strategies.
  • Further research into RAF1 inhibition could lead to novel treatments for undruggable KRAS-mutant tumors.